Endogenous hyperinsulinemic hypoglycemia as a case report: noninsulinoma pancreatogenic hypoglycemia syndrome (NIPHS)
DOI:
https://doi.org/10.32818/reccmi.a9n2a13Keywords:
hyperinsulinism, hypoglycemia, pancreatogenousAbstract
Endogenous hyperinsulinemic hypoglycemia in non-diabetic people is a cause to take into account in nondiabetic patients with hypoglycemia. Its interest lies in its low incidence and the importance of recognizing its
diagnosis and treatment. We present the case of a 40-year-old woman with frequent episodes of hypoglycemia
whose definitive diagnosis was non-insulinoma pancreatogenous hypoglycemia using the oral glucose overload test, which showed abnormally high insulin and C-peptide values in relation to capillary blood glucose. In
our case, the resolution of the symptoms took place with medical treatment (lanreotide).
Downloads
Metrics
References
Iqbal F, Witczak J. Noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) – a therapeutic challenge. Endocrine Abstracts. 2022; 82: 5. https://doi.org/10.1530/endoabs.82.p5 (último acceso jul. 2024). DOI: https://doi.org/10.1530/endoabs.82.P5
Ng CL. Hypoglycaemia in nondiabetic patients – an evidence based ap¬proach. Aust Fam Physician. 2010; 39(6): 399-404. Accesible en: https:// www.racgp.org.au/getattachment/e5311638-b32d-4a11-88b3-9a35e¬e268d83/Hypoglycaemia-in-nondiabetic-patients-an-evidence.aspx. (últi¬mo acceso jul. 2024).
Davi MV, Pia A, Guarnotta V, Pizza G, Colao A, Faggiano A; NIKE Group. The treatment of hyperinsulinemic hypoglycaemia in adults: an update. J En¬docrinol Invest. 2017; 40(1): 9-20. doi: https://doi.org/10.1007/s40618-016- 0536-3 (último acceso jul. 2024). DOI: https://doi.org/10.1007/s40618-016-0536-3
De Leon DD, Arnoux JB, Banerjee I, Bergadá I, Bhatti T, Conwell LS, et al. Inter¬national Guidelines for the Diagnosis and Management of Hyperinsulinism. Horm Res Paediatr. 2023. doi: https://doi.org/10.1159/000531766 (último acceso jul. 2024). DOI: https://doi.org/10.1159/000531766
Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Servi¬ce FJ. Endocrine Society. Evaluation and management of adult hypoglyce¬mic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endo¬crinol Metab. 2009; 94(3): 709-28. doi: https://doi.org/10.1210/jc.2008-1410 (último acceso jul. 2024). DOI: https://doi.org/10.1210/jc.2008-1410
Anderson B, Nostedt J, Girgis S, Dixon T, Agrawal V, Wiebe E, et al. Insulinoma or non-insulinoma pancreatogenous hypoglycemia? A diagnostic dilem¬ma. J Surg Case Rep. 2016; 2016(11): rjw188. doi: https://doi.org/10.1093/ jscr/rjw188 (último acceso jul. 2024). DOI: https://doi.org/10.1093/jscr/rjw188
Anlauf M, Wieben D, Perren A, Sipos B, Komminoth P, Raffel A, et al. Persis¬tent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblas¬tosis: diagnostic criteria, incidence, and characterization of beta-cell chan¬ges. Am J Surg Pathol. 2005; 29(4): 524-533. doi: https://doi.org/10.1097/01. pas.0000151617.14598.ae (último acceso jul. 2024). DOI: https://doi.org/10.1097/01.pas.0000151617.14598.ae
Witteles RM, Straus II FH, Sugg SL, Koka MR, Costa EA, Kaplan EL. Adult-onset nesidioblastosis causing hypoglycemia: an important clinical en¬tity and continuing treatment dilemma. Arch Surg. 2001; 136(6): 656- 663. doi: https://doi.org/10.1001/archsurg.136.6.656 (último acceso jul. 2024). DOI: https://doi.org/10.1001/archsurg.136.6.656
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 María Fernández-Riesgo, Javier Ena, Isabel Selles, Roberto Abellán-Ponce, José Ramón Domínguez-Escribano
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
